Completed PHASE1 INTERVENTIONAL 10-arm NCT04236778

First-in-human Study of VE303 in Healthy Adult Volunteers

A Phase 1a/1b, First-in-human, Open-label Study of Escalating Doses of VE303 in Healthy Adult Volunteers With or Without Vancomycin Pre-treatment to Evaluate Safety, Dosing, and Pharmacodynamics

Sponsor: Vedanta Biosciences, Inc.

Conditions Healthy Volunteers

Interventions Oral Vancomycin VE303

Updated 4 times since 2020 Last updated: Jan 22, 2020 Started: Nov 28, 2017 Primary completion: Mar 11, 2019 Completion: Mar 11, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by Vedanta Biosciences, Inc. and has accumulated 4 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Feb 2020 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vedanta Biosciences, Inc.

Data source: Vedanta Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States